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Abstract
Background: Previous studies have shown that the minor allele (C allele) for Cry 1 rs2287161, may be associated
with increased risk of cardiovascular diseases (CVDs). Low resting metabolic rate (RMR) caused by the diet has been
shown to have, potentially, unfavorable effects on obesity. This study sought to investigate the interactions
between the Cry 1 Gene and fat intake on RMR in women with overweight of obesity.
Methods: This comparative cross-sectional study was conducted on 377 Iranian women with overweight of
obesity. A food frequency questionnaire (FFQ), with 147 items, was used to assess dietary intake. Individuals were
categorized into two groups based on the rs2287161 genotype. Body composition, dietary intake, and RMR were
assessed for all participants.
Results: There was a significant difference between genotypes for fasting blood sugar (FBS) (P = 0.04), fat free mass
(FFM) (P = 0.0009), RMR per FFM (P = 0.05), RMR per body mass index (BMI) (P = 0.02), and RMR deviation (P = 0.01).
Our findings also showed significant interactions between total fat and C allele carrier group on RMR per kg body
weight, RMR per body surface area (BSA), RMR per FFM, and RMR deviation (P for interaction < 0.1), in addition to a
significant interaction between CC + CG group genotype and polyunsaturated fatty acids (PUFA) intake on RMR per
BMI (P for interaction =0.00) and RMR per kg (P for interaction = 0.02) and RMR per BSA (P = 0.07), compared to the
GG group, after control for confounder factors.
Conclusion: These results highlight that dietary compositions, gene variants, and their interaction, should be
acutely considered in lower RMR.
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Introduction
The prevalence of overweight and obesity has increased
such that almost one-third of the global population is
now categorized as overweight or obese [1, 2]. Globally,
obesity is almost 50% more prevalent among women [3,
4], primarily attributed due to a 3–5% lower resting
metabolic rate (RMR) compared to men [5]. Obesity
may be defined by an abnormal or excessive fat accumu-
lation that leads to health impairment [6]. Moreover,
obesity is associated with diabetes mellitus, cardiovascu-
lar diseases (CVDs) and some types of cancer [7–9], Pre-
vious studies propose the contribution of genetics,
dietary, and environmental factors may play a significant
role in the pathogenesis of obesity [10–13].
It has been theoretically demonstrated that individuals
with low resting metabolic rate (RMR) are at increased
risk of developing obesity-related disorders, since a lar-
ger portion of their daily food intake is stored as fat [14,
15]. RMR is affected by age, sex, body weight, pregnancy
and hormonal status [16]. Indeed, RMR accounts for
60% of total energy expenditure (TEE) in individuals
with sedentary habits [17], and it is highly determined
by body composition, specifically fat-free mass (FFM)
[18]. Energy intake and FFM are strongly linked [19],
and, by extension, RMR is associated with energy intake
[20]. Indeed, as adipose tissue increases in obese adults,
fat mass (FM) poses a greater influence on RMR [21].
Different body composition indices, such as weight, lean
body mass and body cell mass are inter-related [22],
thus, various ratios of RMR are used among individuals.
The human circadian clock is responsible for the co-
ordination between energy intake and metabolism based
on changes in external factors including sunset/sunrise,
physical activity, and dietary intake [23–25]. Recent find-
ings show that regulation of metabolism by the circadian
clock and its components is reciprocal. At the molecular
level, the central circadian clock consists of Clock (circa-
dian locomotor output cycles kaput), Bmal1 (brain and
muscle Arnt like protein-1), Per (period)1,2,3, and
Cry1,2 (cryptochrome) genes [26]. According to experi-
mental studies, Cry1 plays a major role in lipid metabol-
ism [27]. Indeed, hepatic depletion of CRY proteins
increases circulating glucose, and their overexpression
leads to a decrease in fasting blood glucose and improve-
ment of insulin resistance in obese mice [28]. As part of
circadian rhythmicity, these genes interact with the daily
pattern of food intake [29]. It has previously been shown
that Cry-deficient mice were more susceptible to obesity
following a high-fat diet, than non-deficient counterparts
[30]. Furthermore, a reduction of serum leptin due to
any maladjustment of circadian rhythm and high fat
diet-induced hyperinsulinemia, which stimulates
lipogenesis, could alter energy homeostasis [30, 31]. It
must be mentioned that circadian rhythm regulates
metabolism via linking the Suprachiasmatic nucleus
(SCN) to energetic c enters in the hypothalamus and
brain stem. Conversely, metabolism regulates the circa-
dian system; hormones that regulate metabolism can
persuade or unset circadian rhythms [32, 33]; indeed, ex-
pression of Bmal1, Per2, and Cry1 in human subcutane-
ous and visceral fat [24] could lead to insulin resistance,
inflammatory responses, reduced RMR, and higher body
weight [34, 35].
Some studies have reported that RMR rate have de-
pends on genetic factor and diet especially fat. Overall,
some recent research, diet such as high-fat diet can have
an interaction with CRY1 gene polymorphism [25, 36,
37]. Besides, previous studies show the CRY1 variant is
associated with obesity and insulin resistance [38]. Al-
though the exact mechanism underlying the association
between RMR and IR has not been clear yet, recent data
has indicated that a central pacemaker in the circadian
system plays a role in controlling glucose homeostasis
and energy metabolism basically along with each other
[39]. Energy expenditure, which is tightly regulated by
circadian rhythm, has a key role in obesity [40].
To our knowledge, there is currently no study that has
investigated the association between Cry1, diet, and en-
ergy expenditure. Thus, given the potential future im-
portance to clinical practice, we sought to assess the
interaction of Cry1 and high-fat diet with RMR in
women with overweight of obesity.
Methods
Study population
This cross-sectional study was conducted in 377 women,
who were referred to health centers in Tehran, Iran from
2017 to 2019. Participants who had, self-certified, good
general health were included in the study. The age of
women ranged between 18 and 48 years, and their body
mass index (BMI) ranged between 25 and 45 kg/m2. The
exclusion criteria were; history of diabetes mellitus,
hypertension, CVDs or fatty liver, taken all types of
medicine including an oral contraceptive pill, smoking,
intake of alcohol, pregnancy, currently lactating, and
post menopause. We also excluded participants if
chronic disease affected their diet, were following an ar-
bitrary special dietary regimen, had weight fluctuations
in the past 1 year, and if they were on a specific diet or if
their daily energy intake was < 800 kcal or > 4200 kcal
[41]. Anthropometrics, RMR measurements, biochemical
markers, and DNA extraction were measured in the
school of Nutritional Sciences and Dietetics at Tehran
University of medical sciences (TUMS). Before commen-
cing in this study, each participant signed a written in-
formed consent form. Ethical approval, and associated
number IR.TUMS.VCR.REC.1398.051 was obtained from
the Ethics Commission of the TUMS.
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Assessment of high fat intake
A semi-quantitative, standard food frequency question-
naire (FFQ) was used to assess dietary intake, which was
previously validated and adapted for this population
[42]. The FFQ included 147 foods commonly consumed
by Iranians, which were defined by standard serving sizes
for each food item. FFQ data were collected through
face-to-face interviews by trained interviewers at the
health centers in Tehran. The software program, Nutri-
tionist IV, was used for nutrient analysis, and was modi-
fied for Iranian foods [43].
To calculate fat intake, we first adjusted fat intake to
energy, and then the associated percentage was calcu-
lated as the total daily caloric intake, where above 30%
was defined as high fat intake and < 30% defined as low
fat intake. Also, for saturated fatty acid (SFA) and poly-
saturated fatty acid (PUFA), medians of SFA (Low <
25.76 g/d, High ≥25.76) and PUFA (Low < 18.8, High
≥18.81) intake were applied in statistical analysis.
Anthropometric measurements
Weight was measured using a digital weighing scale,
where participants wore light indoor clothing, were un-
shod, and recorded to the nearest 100 g. Height was
measured to the nearest 0.5 cm while participants were
in the normal standing position, without shoes, using a
standard stadiometer (Seca, Germany). Waist circumfer-
ence (WC) was measured at the umbilicus and recorded
to the nearest 0.5 cm. A plastic tape measure was used
to assess and hip circumferences (HC), to the nearest
0.5 cm, then, the ratio between waist and hip (WHR) cir-
cumferences was calculated. BMI was computed from
the height and weight data, using the standard, weight
(kg)/height2 (m2), equation.
Resting metabolic rate (RMR) measurement
Resting metabolic rate was measured for all participants
by a trained and experienced nutritionist using indirect
calorimetry spirometer MetaLyzer 3B-R3 (Cortex. Bio-
physik GmbH, Leipzig, Germany). According to the
manufacturer’s instructions, gas ventilation and ex-
change was calibrated before each test. High-resolution
spiroergometric systems, with an infrared sensor, were
used for CO2 evaluation and an amperometric solid elec-
trolyte sensor for O2 evaluation, which were both re-
corded continuously through breath-by-breath gas
analysis. Utilizing an ergonomically designed mask, a
small portion of breathed air was conducted through the
volume flow sensor. The RMR is evaluated by measuring
the amount of O2 consumed and CO2 produced. Sub-
jects were asked to avoid caffeine or alcohol consump-
tion and vigorous exercise for a day and 12 h fasting
before RMR measurements was required. The RMR was
measured in the morning after a restful night’s sleep in a
silent room with an ambient temperature of 24–26 °C.
After achieving steady state in the supine position in a
quiet and darkened atmosphere, the RMR was measured
for 30 min. Gas exchange and ventilation were recorded
continuously via breath-by-breath gas analysis. The oxy-
gen uptake (VO2) and respiratory exchange ratio were
analyzed within the last 20 min of the resting period and
during a minimum of 5 consecutive minutes in steady-
state conditions. Predictive RMR was determined using
the Harris-Benedict equation, which considers the
weight, height, and age of participants [44]. Participants
were classified to two groups, low and high RMR, based
on median values for; RMR per body surface area (BSA)
(854.50), RMR deviation (− 8.00), RMR per BMI (50.90),
and RMR per FFM (33.73), and 20 kcal/24 h /kg for
RMR per kg body weight, according to the findings as
reported previously in detail [45].
Assessment of other variables
The International Physical Activity Questionnaire
(IPAQ) was used to assess Physical Activity (PA), and
was reported as metabolic equivalent hours per week
(METs h/week) [46]. Activity levels were classified into
low (< 600METs), moderate (600–3000 METs), and high
(≥3000 METs) levels, according to the IPAQ scoring
protocol. A demographic questionnaire (information on
age, marital status, education, economic and job status)
at study commencement.
DNA extraction and sequencing of the gene
The Cry 1 gene primer was selected based on a previous
study [47]. All participants from whom deoxyribonucleic
acid (DNA) samples were accessible, were evaluated to
be genotyped for the rs2287161. According to the manu-
facturer’s protocol, we extracted genomic DNA from
blood samples with the use of the Mini Columns, Type
G kit (GeneALL, Exgene) The concentration and quality
of the extracted DNA were assessed by the use of a
Nano Drop ND-2000 spectrometer. The rs2287161
(minor allele: C; major allele: G) was genotyped by poly-
merase chain reaction-restricted length polymorphism
(PCR–RFLP) technique. PCR applied the following
primers: forward 5′-GGAACAGTGATTGGCTCTAT
CT − 3′; reverse 5′-GGTCCTCGGTCTCAAGAAG-3′.
PCR reactions were performed in a final volume of 20 μl
include of 2 μl primers, 1 μl extracted DNA,7 μl distilled
water, and 10 μl Taq DNA Polymerase Master Mix
(Amplicon; Denmark) with the next conditions in a
DNA thermocycler: The DNA templates were denatured
at 94 °C for 4 min; amplification contained of 35 cycles at
94 °C, 58 °C and 72 °C (each stage for 30 s), with a final
extension at 72 °C for 7 min. Amplified DNA (10 μl) was
mixed with 2 μl of DRI restriction enzyme (Thermo
Fisher Scientific; USA) at 37 °C. To ensure the PCR
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process and amplification of the desired parts, PCR
products electrophoresis was performed on agarose gel.
Fragments including three possible genotypes were then
determined: uncut homozygous GG (107 bp), cut hetero-
zygous GC (107,48 and 226 bp), and cut homozygous
CC (155 and 226 bp). In order to examine the interac-
tions between fat intake, SFA, PUFA intake, and Cry 1
polymorphisms on RMR, the participants were grouped
based on Cry 1 polymorphisms: group 1 with GG
(rs2287161) genotype (n = 107), group 2 or C allele car-
rier group with CC and GC genotype (n = 270).
Laboratory tests
All samples were collected, after 10–12 h fasting, at the
laboratory of the school of Nutritional and Dietetics at
TUMS. Fasting serum glucose, insulin, total cholesterol,
triglyceride (TG), low density lipoprotein (LDL), and
high density lipoprotein (HDL) were measured from
blood samples. IR was calculated by the homeostatic
model assessment (HOMA) according to the following
equation: HOMA-IR = [fastingplasma glucose (mmol/l) *
fasting plasma insulin (mIU/l)]/22.5.
Statistical analysis
The Hardy-Weinberg equilibrium and comparison of
categorical variables were assessed with the χ2 test. De-
scriptive statistics, including the mean (standard devi-
ation) and frequency summaries, were used to describe
the study population. A total of 377 Iranian women with
overweight of obesity were categorized based on
rs2287161genotypes and divided into two groups ac-
cording to dominant genetic model (risk allele carriers
CG +GC genotype (n = 270) versus homozygous non-
risk allele GG genotype (n = 107). Comparisons between
groups were made using the independent t-test for con-
tinuous variables and chi-square test for categorical vari-
ables. Moreover, age, BMI, IPAQ, and energy intake-
adjusted analyses were performed using general linear
models (ANCOVA). Moreover, to analyze the potential
interactions between genotype and diet intake, and the
genotype and fat, PUFA or SFA, an interaction term of
genotype x fat, SFA or PUFA dietary intake on types of
RMR was included in the binary logestic regression. For
this analysis, the GG genotype and categories of lower
intake of total fat, PUFA, SFA were considered as refer-
ence groups. Data were analyzed using IBM SPSS ver-
sion 23 (SPSS, Chicago, IL, USA). P-values for all
variables were reported before the adjustment in the
crude model by by independent T-test and after adjust-
ment with potential confounders as age, BMI, physical
activity, and energy intake using analysis of covariance
(ANCOVA). P < 0.05 was considered statistically signifi-
cant, but for interactions, P < 0.1 was considered
significant.
Results
Study population characteristics
The present study was conducted on 377 obese and
overweight Iranian women, of which, 70.8% were mar-
ried, 36.2% occupied, 86.6% had a college education, and
45.8% had good economic status. The mean age, weight,
BMI, WHR, WC, body fat mass (BFM), FFM were 36.67
± 9.10 years, 81.29 ± 12.43 kg, 31.26 ± 4.29 kg/m2, 1.16 ±
4.54, 99.61 ± 10.07 cm, 34.74 ± 8.75 kg, 46.52 ± 5.71 kg,
respectively. The mean of RMR in the study population
was 1574.96 ± 259.71. The median of RMR groups for
binary analysis was considered for analysis as following
RMR per BSA (854.50), RMR deviation (− 8.00), RMR
per BMI (50.90), and RMR per FFM (33.73), and for
RMR per kg body weight was [20], respectively. Also, the
mean intake of total dietary fat intake was 95.13 ± 35.17
g, SFA 28.40 ± 7.43 g, and PUFA 20.08 ± 7.57 g, respect-
ively. The overall prevalence of rs2287161 genotypes in
participants for CC+ CG and GG was 66.8 and 26.5%,
respectively.
Study participant characteristics between genotype of
rs2287161
Comparison of participant’s variables based on
rs2287161 genotypes was shown in Table 1. After geno-
type classification, we found significant differences in the
crude model among genotypes for age (P = 0.03), FFM
(P = 0.00), BMI (P = 0.06), RMR per BMI (P = 0.02),
RMR per FFM (P = 0.05) RMR deviation (P = 0.01), FBS
(P = 0.04), marriage status (P = 0.07), economic status
(P = 0.01), and physical activity (P = 0.04).
Also, after controlling for confounders, age remained
marginally significant (P = 0.07) with a higher mean in
the group with risk allele group (CC + CG), and in edu-
cation status (P = 0.01). For all other variables, no sig-
nificant association was observed (Table 1).
Association between general characteristics of
participants in three grouped of SFA (gr/d), PUFA (gr/d),
and fat intake (gr/d) among the population
General characteristics of participants, such as body
composition, biochemical assessment, RMR measure-
ment, and others among lower vs. higher than the me-
dian of total fat, trans fatty acid (TFA), and
polyunsaturated fatty acid (PUFA) intake, are presented
in Table 2.
General characteristics of participants among SFA intake
categories
In the crude model, in body composition variables there
were significant mean differences for BFM (P = 0.04),
WC (P = 0.02), and in biochemical variables; TG (P = <
0.001). Among SFA categories, there was a significant
mean difference for marriage status (P = 0.02). After
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Table 1 Characteristics of study population according to rs2287161 genotypes
Variables rs2287161 genotypes
CC + CG
(n = 270 (
GG
(n = 107)
p-value* p-value**
Age (year) 37.31 ± 9.40 35.03 ± 8.30 0.03 0.07
Body composition
Weight (kg) 81.29 ± 12.31 80.01 ± 11.57 0.35 0.80
Height (cm) 160.88 ± 5.73 161.81 ± 5.66 0.15 0.72
FFM (kg) 46.36 ± 5.64 46.46 ± 5.58 0.00 0.70
BMI (kg/m2) 31.40 ± 4.24 30.53 ± 4.04 0.06 0.87
BFM (kg) 35.01 ± 8.72 33.48 ± 7.88 0.11 0.77
WHR 0.93 ± 0.05 0.93 ± 0.05 0.41 0.43
WC (cm) 99.82 ± 9.99 98.30 ± 9.39 0.17 0.52
RMR measurement
RMR (kcal/day) 1568.58 ± 247.09 1586.30 ± 278.82 0.59 0.77
RQ 0.85 ± 0.043 0.85 ± 0.03 0.76 0.82
RMR per Kg body weight
(kcal/day/kg)
19.64 ± 3.06 19.87 ± 3.16 0.55 0.98
RMR per BSA
(kcal/day/m2)
850.57 ± 106.57 857.47 ± 127.64 0.64 0.83
RMR per BMI
(kcal/day/kg/m2)
51.14 ± 8.09 52.38 ± 9.71 0.02 0.86
RMR per FFM
(kcal/day/kg)
33.76 ± 4.14 34.14 ± 4.99 0.05 0.97
RMR deviation
(%)
−8.38 ± 11.89 −7.79 ± 13.91 0.01 0.99
Biochemical assessment
FBS (mg/dL) 88.39 ± 10.30 85.71 ± 7.97 0.04 0.11
HOMA-IR (mg/dL) 3.38 ± 1.30 3.36 ± 1.26 0.91 0.56
TC (mg/dL) 184.07 ± 34.45 187.22 ± 38.26 0.52 0.09
HDL (mg/dL) 46.57 ± 11.58 46.16 ± 9.92 0.78 0.46
LDL (mg/dL) 94.80 ± 24.39 95.14 ± 23.94 0.91 0.83
TG (mg/dL) 118.89 ± 59.06 118.39 ± 60.44 0.95 0.88
hs CRP (mg/L) 4.30 ± 4.80 3.93 ± 3.90 0.57 0.66
IPAQ
Low 82 (70.7%) 39 (29.3%) 0.04 0.98
Moderate 100 (65.4%) 40 (34.6%)
High 41(35.4%) 75 (64.6%)
History of weight loss in past years
Yes 86 (31.8%) 122 (68.2%) 0.08 0.13
No 49 (24.5%) 120 (75.5%)
Quantitative variables were reported with mean and SD and qualitative variables with number and percentage
*P values resulted from the independent T.test for continuous variables and chi-square test for categorical variables
**P-value is found by ANCOVA and adjusted for age, BMI, physical activity, and total energy intake
BMI body mass index, WC waist circumference, WHR waist-to-hip ratio, FFM fat free mass, HDL high density lipoprotein, hs-CRP high-sensitivity C reactive protein,
LDL low density lipoprotein, BMR basal metabolic rate, TG triacylglycerol, TC total cholesterol, PUFA poly unsaturated fatty acid, SAFA saturated fatty acid, HOMA
homeostatic model assessment, GLU Glucose, RMR resting metabolic rate, RQ respiratory quotient, RMR/BSA resting metabolic rate per body surface area, RMR/FFM
resting metabolic rate per fat free mass, RMR/BMI resting metabolic rate per body mass index
Cut point IPAC: low < 600 METs, moderate:600–3000 METs, high> 3000 METs
Mirzababaei et al. BMC Endocrine Disorders          (2021) 21:196 Page 5 of 14
Ta
b
le
2
G
en
er
al
ch
ar
ac
te
ris
tic
s
of
pa
rt
ic
ip
an
ts
in
th
re
e
gr
ou
pe
d
of
SF
A
(g
r/
d)
,P
U
FA
(g
r/
d)
,a
nd
fa
t
in
ta
ke
(g
r/
d)
am
on
g
st
ud
ie
d
po
pu
la
tio
n
V
ar
ia
b
le
s
SF
A
in
ta
ke
(g
r/
d
)
PU
FA
in
ta
ke
(g
r/
d
)
To
ta
lF
at
In
ta
ke
(%
)
Lo
w
<
25
.7
6
H
ig
h
≥
25
.7
6
p- va
lu
e*
p- va
lu
e*
*
Lo
w
<
18
.8
1
H
ig
h
≥
18
.8
1
p- va
lu
e*
p- va
lu
e*
*
Lo
w
<
30
%
H
ig
h
≥
30
%
p- va
lu
e*
p- va
lu
e*
*
A
g
e
(y
ea
r)
37
.2
4
±
9.
15
36
.4
2
±
9.
23
0.
40
0.
27
37
.2
9
±
9.
19
36
.1
0
±
9.
21
0.
20
0.
15
35
.4
6
±
9.
07
37
.3
2
±
9.
07
0.
05
0.
78
B
od
y
co
m
p
os
it
io
n
W
ei
g
ht
(k
g
)
81
.3
8
±
10
.9
9
81
.0
6
±
12
.8
6
0.
80
0.
97
81
.1
7
±
12
.0
2
81
.1
6
±
12
.5
2
0.
99
0.
85
82
.6
1
±
13
.1
1
80
.5
9
±
12
.0
2
0.
12
0.
59
H
ei
g
ht
(c
m
)
16
1.
00
±
5.
70
16
1.
22
2
±
5.
98
0.
73
0.
48
16
1.
52
±
6.
06
16
0.
77
±
5.
69
0.
20
0.
64
16
2.
13
±
5.
58
16
0.
74
±
5.
96
0.
02
0.
76
FF
M
(k
g)
47
.0
2
±
5.
68
46
.2
3
±
5.
65
0.
19
0.
52
46
.8
4
±
5.
57
46
.1
5
±
5.
75
0.
22
0.
54
47
.4
8
±
5.
75
46
.0
1
±
5.
63
0.
10
0.
95
B
M
I(
kg
/m
2
)
31
.4
6
±
3.
93
31
.1
8
±
4.
47
0.
24
0.
60
31
.1
4
±
4.
31
31
.4
0
±
4.
30
0.
56
0.
73
31
.4
5
±
4.
52
31
.4
5
±
4.
17
0.
50
0.
72
B
FM
(k
g
)
34
.6
2
±
7.
52
34
.7
8
±
9.
30
0.
04
0.
99
34
.3
4
±
8.
58
35
.1
2
±
8.
90
0.
32
0.
39
35
.2
5
±
9.
43
34
.4
6
±
8.
37
0.
38
0.
35
W
H
R
0.
93
±
0.
04
1.
28
±
5.
64
0.
47
0.
29
1.
40
±
6.
52
0.
93
±
0.
05
0.
05
0.
90
0.
93
±
0.
05
1.
28
±
5.
63
0.
46
0.
14
W
C
(c
m
)
99
.6
8
±
8.
86
99
.5
4
±
10
.6
4
0.
02
0.
90
99
.7
3
±
9.
73
99
.4
4
±
10
.4
2
0.
77
0.
91
10
0.
37
±
10
.3
6
99
.2
0
±
9.
91
0.
26
0.
39
B
io
ch
em
ic
al
as
se
ss
m
en
t
FB
S
(m
g/
d
L)
86
.9
8
±
9.
26
87
.7
5
±
9.
82
0.
55
0.
53
87
.1
8
±
9.
67
87
.8
3
±
9.
60
0.
59
0.
67
86
.3
7
±
8.
06
77
.0
8
±
10
.3
6
0.
18
0.
11
H
O
M
A
-I
R
(m
g/
d
L)
3.
28
±
1.
20
3.
46
±
1.
45
0.
33
0.
02
3.
34
±
1.
20
3.
32
±
1.
35
0.
89
0.
73
3.
31
±
1.
04
3.
37
±
1.
37
0.
74
0.
27
TC
(m
g
/d
L)
18
2.
49
±
32
.2
7
18
6.
50
±
38
.1
4
0.
41
0.
28
18
9.
47
±
38
.1
2
18
0.
53
±
33
.6
9
0.
05
0.
10
18
4.
64
±
37
.1
4
18
6.
54
±
33
.1
6
0.
68
0.
06
H
D
L
(m
g/
d
L)
45
.0
6
±
10
.4
5
47
.6
9
±
10
.9
6
0.
07
0.
12
45
.7
7
±
11
.4
5
47
.9
0
±
9.
99
0.
12
0.
23
46
.7
6
±
11
.9
0
46
.4
8
±
10
.3
1
0.
84
0.
48
LD
L
(m
g/
d
L)
90
.7
5
±
21
.5
3
97
.2
0
±
25
.2
2
0.
01
0.
02
95
.5
1
±
24
.5
1
94
.5
1
±
23
.9
3
0.
74
0.
46
94
.6
7
±
22
.5
0
95
.6
3
±
24
.9
9
0.
76
0.
38
TG
(m
g
/d
L)
13
2.
74
±
74
.8
4
11
2.
98
±
51
.6
7
<
0.
00
1
0.
87
12
2.
15
±
59
.4
5
11
5.
14
±
60
.3
2
0.
36
0.
95
12
8.
24
±
66
.3
7
11
3.
23
±
54
.4
7
0.
05
0.
63
hs
.C
RP
(m
g
/L
)
3.
70
±
4.
01
4.
62
±
4.
92
0.
15
0.
08
3.
94
±
4.
51
4.
69
±
4.
77
0.
22
0.
63
4.
39
±
4.
42
4.
32
±
4.
74
0.
91
0.
81
RM
R
m
ea
su
re
m
en
t
RM
R
(k
ca
l/
d
ay
)
15
65
.0
8
±
24
1.
12
15
82
.9
3
±
26
8.
67
0.
58
0.
30
15
66
.8
8
±
25
9.
51
15
86
.7
4
±
25
9.
88
0.
51
0.
39
15
90
.7
8
±
25
6.
01
15
66
.8
9
±
26
1.
85
0.
45
0.
16
RQ
0.
85
±
0.
04
0.
85
±
0.
04
0.
75
0.
88
0.
85
±
0.
04
0.
85
±
0.
04
0.
66
0.
27
0.
85
±
0.
0
0.
85
±
0.
04
0.
79
0.
75
RM
R
p
er
K
g
b
od
y
w
ei
g
ht
(k
ca
l/
da
y/
kg
)
19
.3
8
±
3.
16
19
.7
9
±
3.
09
0.
30
0.
15
19
.5
7
±
3.
17
19
.7
3
±
3.
07
0.
67
0.
26
19
.5
3
±
3.
24
19
.6
2
±
3.
03
0.
81
0.
33
RM
R
p
er
B
SA
(k
ca
l/
da
y/
m
2
)
84
6.
30
±
11
6.
32
85
5.
46
±
11
6.
32
0.
52
0.
31
84
7.
98
±
11
5.
27
85
6.
68
±
11
4.
02
0.
52
0.
35
85
3.
25
±
11
1.
15
84
8.
66
±
11
5.
51
0.
80
0.
20
RM
R
p
er
B
M
I
(k
ca
l/
da
y/
kg
/m
2
)
50
.8
0
±
9.
00
51
.6
6
±
8.
76
0.
43
0.
24
51
.3
4
±
8.
93
51
.4
1
±
8.
77
0.
94
0.
43
51
.6
8
±
8.
79
51
.0
8
±
8.
74
0.
90
0.
18
RM
R
p
er
FF
M
(k
ca
l/
da
y/
kg
)
33
.2
8
±
4.
31
34
.1
3
±
4.
57
0.
12
0.
11
33
.2
6
±
4.
13
34
.4
2
±
4.
77
0.
02
0.
05
33
.5
7
±
4.
33
33
.8
6
±
4.
55
0.
46
0.
06
RM
R
d
ev
ia
ti
on
−
9.
26
±
12
.9
4
−
7.
74
±
12
.5
6
0.
34
0.
22
−
8.
56
±
13
.1
8
−
7.
95
±
12
.2
2
0.
69
0.
39
−
8.
44
±
12
.5
9
−
8.
49
±
12
.4
4
0.
97
0.
28
Mirzababaei et al. BMC Endocrine Disorders          (2021) 21:196 Page 6 of 14
Ta
b
le
2
G
en
er
al
ch
ar
ac
te
ris
tic
s
of
pa
rt
ic
ip
an
ts
in
th
re
e
gr
ou
pe
d
of
SF
A
(g
r/
d)
,P
U
FA
(g
r/
d)
,a
nd
fa
t
in
ta
ke
(g
r/
d)
am
on
g
st
ud
ie
d
po
pu
la
tio
n
(C
on
tin
ue
d)
V
ar
ia
b
le
s
SF
A
in
ta
ke
(g
r/
d
)
PU
FA
in
ta
ke
(g
r/
d
)
To
ta
lF
at
In
ta
ke
(%
)
Lo
w
<
25
.7
6
H
ig
h
≥
25
.7
6
p- va
lu
e*
p- va
lu
e*
*
Lo
w
<
18
.8
1
H
ig
h
≥
18
.8
1
p- va
lu
e*
p- va
lu
e*
*
Lo
w
<
30
%
H
ig
h
≥
30
%
p- va
lu
e*
p- va
lu
e*
*
(%
)
IP
A
Q Lo
w
40
(3
2.
0%
)
85
(6
8.
0%
)
0.
15
0.
39
64
(5
1.
2%
)
61
(4
8.
8%
)
0.
80
0.
87
40
(3
1.
5%
)
87
(6
8.
5%
)
0.
7
0.
51
M
od
er
at
e
36
(3
1.
3%
)
79
(6
8.
7%
)
54
(4
7%
)
64
(5
3%
)
41
(3
4.
5%
)
78
(6
5.
5%
)
H
ig
h
7
(5
8.
3%
)
5
(4
1.
7%
)
6
(5
0%
)
6
(5
0%
)
3
(4
1.
7%
)
7
(5
8.
3%
)
rs
22
87
16
1
g
en
ot
yp
es
C
C
+
G
C
88
(3
3.
3%
)
17
6
(6
6.
7%
)
0.
46
0.
93
12
9
(4
8.
9%
)
13
5
(5
1.
1%
)
0.
48
0.
79
93
(3
4.
4%
)
17
7
(6
5.
5%
)
0.
63
0.
94
G
G
37
(3
8.
6%
)
63
(6
2.
4%
)
54
(5
3.
5%
)
47
(4
6.
5%
)
40
(3
7.
4)
67
(6
2.
6%
)
H
is
to
ry
of
w
ei
g
ht
lo
ss
in
p
as
t
ye
ar
s
Y
es
69
(3
5.
4%
)
12
6
(6
4.
6%
)
0.
18
0.
56
95
(4
8.
7%
)
10
0
(5
1.
3%
)
0.
67
0.
32
70
(3
5.
7%
)
12
6
(6
4.
3%
)
0.
72
0.
68
N
o
47
(2
8.
8%
)
11
6
(7
1.
2%
)
83
(5
0.
9%
)
80
(4
9.
1%
)
63
(3
7.
5%
)
10
5
(6
2.
5%
)
Q
ua
nt
ita
tiv
e
va
ria
bl
es
w
er
e
re
po
rt
ed
w
ith
m
ea
n
an
d
SD
an
d
qu
al
ita
tiv
e
va
ria
bl
es
w
ith
nu
m
be
r
an
d
pe
rc
en
ta
ge
va
lu
es
w
er
e
ca
lc
ul
at
ed
by
In
de
pe
nd
en
t
T.
te
st
as
M
ea
n
±
SD
*P
va
lu
es
re
su
lte
d
fr
om
th
e
an
al
ys
is
of
In
de
pe
nd
en
t
T.
te
st
fo
r
co
nt
in
uo
us
va
ria
bl
es
an
d
ch
i-s
qu
ar
e
te
st
fo
r
ca
te
go
ric
al
va
ria
bl
es
.W
e
al
so
pe
rf
or
m
ed
a
Tu
ke
y
te
st
to
co
m
pa
re
ea
ch
ge
no
ty
pe
w
ith
ot
he
r
ty
pe
s
fo
r
co
nt
in
uo
us
va
ria
bl
es
**
P-
va
lu
e
is
fo
un
d
by
A
N
C
O
VA
an
d
ad
ju
st
ed
fo
r
ag
e,
BM
I,
ph
ys
ic
al
ac
tiv
ity
,a
nd
to
ta
le
ne
rg
y
in
ta
ke
BM
Ib
od
y
m
as
s
in
de
x,
W
C
w
ai
st
ci
rc
um
fe
re
nc
e,
W
H
R
w
ai
st
-t
o-
hi
p
ra
tio
,F
FM
fa
t
fr
ee
m
as
s,
H
D
L
hi
gh
de
ns
ity
lip
op
ro
te
in
,h
s-
CR
P
hi
gh
-s
en
si
tiv
ity
C
re
ac
tiv
e
pr
ot
ei
n,
LD
L
lo
w
de
ns
ity
lip
op
ro
te
in
,B
M
R
ba
sa
lm
et
ab
ol
ic
ra
te
,
TG
tr
ia
cy
lg
ly
ce
ro
l,
TC
to
ta
lc
ho
le
st
er
ol
,P
U
FA
po
ly
un
sa
tu
ra
te
d
fa
tt
y
ac
id
,S
FA
sa
tu
ra
te
d
fa
tt
y
ac
id
,H
O
M
A
ho
m
eo
st
at
ic
m
od
el
as
se
ss
m
en
t,
G
LU
G
lu
co
se
,R
M
R
re
st
in
g
m
et
ab
ol
ic
ra
te
,R
Q
re
sp
ira
to
ry
qu
ot
ie
nt
,R
M
R/
BS
A
re
st
in
g
m
et
ab
ol
ic
ra
te
pe
r
bo
dy
su
rf
ac
e
ar
ea
,R
M
R/
FF
M
re
st
in
g
m
et
ab
ol
ic
ra
te
pe
r
fa
t
fr
ee
m
as
s,
RM
R/
BM
Ir
es
tin
g
m
et
ab
ol
ic
ra
te
pe
r
bo
dy
m
as
s
in
de
x
C
ut
po
in
t
IP
A
C
:l
ow
<
60
0
M
ET
s,
m
od
er
at
e:
60
0–
30
00
M
ET
s,
hi
gh
>
30
00
M
ET
s
Mirzababaei et al. BMC Endocrine Disorders          (2021) 21:196 Page 7 of 14
adjusting for potential confounders, women with higher
intake of SFA had significantly higher mean HOMA-IR
(P = 0.02), and LDL(P = 0.02), all other variables were no
longer significant after adjustment. Regarding other vari-
ables related to general characteristics, there were no
significant differences noted (all P > 0.05).
General characteristics of participants among PUFA intake
categories
There was a significant difference in cholesterol between
lower and higher PUFA intake categories before adjust-
ment (P = 0.05), but after controlling for confounders,
this association was not present. There were no signifi-
cant differences in terms of other biochemical assess-
ments, body composition, RMR measurement, education
level, economic status, marital status, rs2287161 geno-
types, physical activity, and job-status (all P > 0.05)
(Table 2).
General characteristics of participants among total fat
intake category
There were significant differences in age (P = 0.05), TG
(P = 0.05), height (P = 0.02), and marriage status (P =
0.02) between lower and higher total fat intake categor-
ies in the crude model, but after controlling for con-
founders (age, BMI, physical activity and total energy
intake), these variables were no longer significant(P >
0.05). There were no significant differences for the
remaining variables before and after adjustment (P >
0.05) (Table 2).
Dietary intake of study population according to
rs2287161 genotypes
The dietary intake of the participants across two groups
of risk allele genotype as GG and GC + CG are shown in
Table 3.
SFA intake was significantly lower in the GG genotype
group compared to the CC + CG group (28.15 vs 28.84
g/day, P = 0.03). Table 3.
The interactions between the intake of total fat, SFA, and
PUFA intake, and rs2287161 genotypes on the different
type of RMR
Interaction between different types of RMRs across total fat
intake category
In the crude models, there was no significant interaction
between CC + CG group genotypes and high fat intake
on odds of RMR per kg body weight compared to the
GG group (β:-0.65, OR:0.51; 95% CI:0.19–1.35, P = 0.18)
but in Model 1, after adjusting for potential confounders,
such as education level, BMI, marriage status, age, his-
tory of weight loss in past year, total energy intake,
Table 3 Dietary intake of study population according to rs2287161 genotypes
rs2287161 genotypes CC + GC
(n = 270)
Mean ± SD
GG
(n = 107)
Mean ± SD
P value P value*
Macronutrient
Energy (kcal) 2635.5 ± 798.17 2739.85 ± 827.69 0.27 –
Protein (gr) 91.98 ± 31.55 93.83 ± 32.08 0.61 0.44
Carbohydrate (gr) 372.11 ± 11.76 392.12 ± 130.94 0.17 0.91
Total fat (gr) 97.63 ± 33.70 95.21 ± 31.31 0.54 0.53
Micronutrient
Trans.fat (gr) 0.0006 ± 0.001 0.0008 ± 0.001 0.87 0.48
Cholesterol (gr) 236.64 ± 111.65 272.52 ± 123.51 0.51 0.93
SAFA (gr) 28.84 ± 11.92 28.15 ± 10.72 0.61 0.03
MUFA (gr) 32.02 ± 12.42 32.74 ± 12.12 0.62 0.60
PUFA (gr) 19.93 ± 8.80 20.70 ± 9.09 0.45 0.94
Oleic (gr) 28.80 ± 11.59 29.37 ± 11.45 0.67 0.58
Linoleic (gr) 17.27 ± 8.21 17.93 ± 8.68 0.49 0.97
Linolenic (gr) 1.20 ± 0.62 1.20 ± 0.59 0.98 0.50
EPA (gr) 0.02 ± 0.03 0.03 ± 0.04 0.35 0.41
DHA (gr) 0.09 ± 0.11 0.10 ± 0.12 0.38 0.45
Total fiber(g) 47.30 ± 21.40 50.18 ± 21.64 0.25 0.56
Variables is presented by mean ± SD
P values resulted from the analysis of Independent T.test
P-value* is obtained by ANCOVA after adjustment for calories intake
PUFA poly unsaturated fatty acid, SAFA saturated fatty acid, MUFA mono saturated fatty acid, EPA Eicosapentaenoic acid, DHA docosahexaenoic acid
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economic status, respiratory quotient (RQ), and physical
activity, the association changed to a significant inter-
action (β:-1.55, OR: 0.21, 95%CI: 0.04–0.98, P = 0.02).
The RMR per BSA variable in the crude model did not
yield a significant interaction (β: -0.97, OR: 0.55, 95%CI:
0.13–1.18, P = 0.28), yet, after controlling for con-
founders, a significant interaction was found (β:-1.49,
OR: 0.28, 95%CI: 0.05–0.92, P = 0.08). In addition, RMR
per FFM was not significant in the crude model (β:
-0.59, OR: 0.55, 95%CI: 0.18–1.64, P = 0.28), but, in the
adjusted model, a significant interaction was found (β:
-1.24, OR: 0.28, 95%CI:0.07–1.16, P = 0.08). Moreover, in
the crude model, there was no significant interaction be-
tween the allele risk group (CC + CG) in comparison
with the reference group (GG) on RMR deviation from
normal (β:-0.77, OR: 0.46, 95%CI: 0.15–1.39, P = 0.17),
however, after controlling for confounders, a significant
interaction was found (β:-1.19, OR: 0.30, 95%CI: 0.07–
1.24, P = 0.09) (Table 4, Fig. 1). No significant inter-
action was found between RMR per BMI and total fat
intake (Table 4).
Interaction between different types of RMRs across PUFA
category
In the crude model, there was a significant interaction
between higher PUFA intake and risk allele(C) genotype
group (CC + CG) in comparison with the reference
group (GG) on RMR per kg body weight (β:-0.96, OR:
0.38 CI:0.04–0.97; P = 0.04), after controlling for con-
founders, this association remained significant (β:-1.65,
OR:0.19 CI:0.04–0.82; P = 0.02), such that in participants
with increased intake of PUFA in the risk alleles group
had 81% lower odds for higher RMR per kg compared to
participants with no allele risk (GG) and a lower intake
of PUFA. Also, for RMR per BSA, there was no signifi-
cant association in the crude model (β: -0.94, OR:0.75
CI:0.13–1.13; P = 0.60), but after adjustment, there we
found a significant interaction between CC + CG group
with higher intake of PUFA, compared to GG group (β:
-1.22, OR:0.29 CI:0.07–1.12; P = 0.07) (Table 4, Fig. 2),
indicating that individuals in the risk allele group with
higher intake of PUFA intake had 71% lower odds for a
higher RMR per BSA compared to the GG group.
Table 4 Investigation of the interactions between intake of Fat, SAFA, and PUFA intake and rs2287161 genotypes on the different
type of RMR
Variables Models Allele High fat intake PUFA intake SAFA intake
β ± SE 95% CI OR P β ± SE 95%CI OR P β ± SE 95%CI OR P
RMR per kg body
weight
(kcal/day/kg)
Crude GG Reference
CG + CC −0.65 ± 0.49 0.19–1.35 0.51 0.18 −0.96 ± 0.48 0.14–0.97 0.38 0.04 −1.02 ± 0.51 0.13–0.97 0.35 0.04
Adjusted GG Reference Reference Reference
CG + CC − 1.55 ± 0.78 0.04–0.98 0.21 0.02 − 1.65 ± 0.74 0.04–0.82 0.19 0.02 − 1.01 ± 0.77 0.08–1.63 0.36 0.18
RMR per BSA
(kcal/day/m2)
Crude GG Reference Reference Reference
CG + CC −0.97 ± 0.56 0.13–1.18 0.55 0.28 − 0.94 ± 0.54 0.13–1.13 0.75 0.60 −0.51 ± 0.56 0.19–1.81 0.50 0.23
Adjusted GG Reference Reference Reference
CG + CC −1.49 ± 0.72 0.05–0.92 0.28 0.08 − 1.22 ± 0.68 0.07–1.12 0.29 0.07 −0.45 ± 0.71 0.15–2.57 0.81 0.77
RMR per BMI
(kcal/day/kg/m2)
Crude GG Reference
CG + CC −0.77 ± 0.55 0.15–1.38 0.46 0.16 −1.38 ± 0.55 0.08–0.73 0.25 0.01 −0.59 ± 0.56 0.18–1.67 0.55 0.29
Adjusted GG Reference Reference Reference
CG + CC −1.09 ± 0.77 0.07–1.52 0.33 0.15 − 1.97 ± 0.75 0.03–0.61 0.13 0.009 −0.63 ± 0.76 0.11–2.35 0.52 0.40
RMR per FFM
(kcal/day/kg)
Crude GG Reference
CG + CC −0.59 ± 0.55 0.18–1.64 0.55 0.28 − 0.27 ± 0.54 0.25–2.20 0.75 0.60 −0.67 ± 0.25 0.16–1.54 0.50 0.23
Adjusted GG Reference Reference Reference
CG + CC −1.24 ± 0.71 0.07–1.16 0.28 0.08 −0.27 ± 0.67 0.20–2.83 0.76 0.68 −0.20 ± 0.71 0.20–3.34 0.81 0.77
RMR Deviation
(%)
Crude GG Reference Reference Reference
CG + CC −0.77 ± 0.56 0.15–1.39 0.46 0.17 − 0.90 ± 0.54 0.13 to 1.18 0.40 0.09 − 0.23 ± 0.56 0.25–2.4 0.79 0.67
Adjusted GG Reference Reference Reference
CG + CC −1.19 ± 0.72 0.07–1.24 0.30 0.09 −1.07 ± 0.68 0.09 to 1.29 0.34 0.11 −0.15 ± 0.71 0.86–3.50 0.86 0.83
GG genotype has 0 risk allele. CG genotype has one and CC genotype have two risk allele
GG genotype is considered as a reference. Low fat, PUFA, SAFA intakes is considered as a reference. The median of RMR groups was considered for analysis as
following RMR/BSA (854.50), deviation normal (−8.00), RMR/BMI (50.90), and RMR/FFM (33.73) and for RMR kg body weight was 20 kcal/24 h/kg
Crude Model: In this model, the effect of any of the confounders is not modified
Model 1: In this model, the effect of education, BMI, marriage status, age, history of weight loss in past years, energy intake, economic status, RQ and physical
activity is adjusted
p value≤0.05
PUFA poly unsaturated fatty acid, SFA saturated fatty acid, RMR resting metabolic rate, RQ respiratory quotient, RMR/BSA resting metabolic rate per body surface
area, RMR/FFM resting metabolic rate per fat free mass, RMR/BMI resting metabolic rate per body mass index
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There was a significant interaction between PUFA
intake with risk allele (C) genotype group (CC + CG)
on RMR per MBI in the crude model (β: -1.38, OR:
0.25 CI:0.08–0.73; P = 0.01), and this remained signifi-
cant after adjustment for potential confounders and
lead to decreased odds (β: -1.97, OR:0.13 CI:0.03–
0.61; P = 0.00). Accordingly, this equated to an 87%
reduction in the odds of higher RMR per BMI in in-
dividuals in the risk allele group (CC + CG) and with
higher intake of PUFA intake, compared to partici-
pants with no allele risk (GG) and a lower intake of
PUFA (Table 4, Fig. 2). We found a significant nega-
tive interaction between the CC + CG group with a
higher intake of PUFA intake (β: -0.90, OR:0.40 CI:
1.18–0.13; P = 0.09), which ameliorated after adjust-
ment for confounding variables (P = 0.11). No other
significant associations were found between PUFA
and RMRs (Table 4).
Interaction between different types of RMRs across SFA
categories
In the crude model, there was a significant interaction
between higher SFA intake and risk allele(C) genotype
group (CC + CG), in comparison with the reference
group (GG), on RMR per kg (β: -1.02, OR:0.35 CI:0.13–
0.97; P = 0.04), however, after controlling for con-
founders, this association was attenuated (β:-1.01, OR:
0.36 CI:0.08–1.63; P = 0.18) (Table 4).
Discussion
The current cross-sectional study was conducted among
women with overweight of obesity to investigate the in-
teractions between the CRY1 gene and fat intake on
RMR. An important factor which can significantly influ-
ence obesity is dietary intake; however, recent research
has indicated that genetic differences and variants in the
human genome may alter energy expenditure and body
Fig. 1 Interaction between dietary fat and Cry 1 genotypes on RMR disorder. Percentage of Types of RMR disorder across GC&CC and CC
genotypes base on low and high dietary fat (% energy). A) Percentage of RMR per kg disorder in low intake across GG and GC&CC genotypes
were respiratory 35.5 and 29.5%, Percentage of RMR/kg disorder in high intake across GG and GC&CC genotypes were respiratory 64.5 and 70.5%.
B) Percentage of RMR per BSA disorder in low intake across GG and GC&CC genotypes were respiratory 38.8 and 28.9%., Percentage of RMR per
BSA disorder in high intake across GG and GC&CC genotypes were respiratory 61.2%and 71.1. C) Percentage of RMR Deviation disorder in low
intake across GG and GC&CC genotypes were respiratory 36.6 and 27.8%., Percentage of RMR Deviation disorder in high intake across GG and
GC&CC genotypes were respiratory 63.4 and 72.2%. D) Percentage of RMR per FFM disorder in low intake across GG and GC&CC genotypes were
respiratory 37.2 and 30.8%., Percentage of RMR per FFM disorder in high intake across GG and GC&CC genotypes were respiratory 62.8and 69.2%.
*P for interaction is for model adjusted (Potential confounders: education level, BMI, marriage status, age, history of weight loss in past year,
energy intake, economic status, RQ, and physical activity)
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weight [48]. Therefore, we hypothesized that individuals
with the CC +GC genotypes may have lower RMR com-
pare to individuals with GG genotypes and a high-fat
diet may interact with this association. Accordingly,
based on our results, Participants with risk allele(C) of
rs228716 genotype group (CC + CG) and higher intake
of total fat were at a 79% lower odds for higher RMR
per kg body weight compared to participants with no al-
lele risk (GG) and a lower intake of fat. Risk allele car-
riers with higher fat intake had 72% lower odds for
higher RMR per BSA compared to no risk allele group.
CC + CG group with a higher intake of total fat com-
pared to the GG group had 72% lower odds for higher
RMR per FFM. There were 70% lower odds for higher
RMR deviation from normal in CC + CG group with
higher intake of total fat intake, compared to the GG
group. We did not detect any significant interaction be-
tween different types of RMRs across SFA and PUFA
categories.
Genetic profile is an informative factor in the etio-
pathogenesis of obesity. In addition to gene polymor-
phisms, which effect on adipogenesis, there are some
gene polymorphisms which can alter the regulation and
level of energy balance [49]. A two year randomized
weight-loss diet trial found a significant relationship be-
tween CRY2 rs11605924 and changes of RMR [50].
Moreover, in the mentioned study, it was found that
dietary fat intake modified the effect of CRY2 in changes
in respiratory quotient (RQ), a parameter of fuel
utilization.
A 3-month low-calorie-diet interventional study
among women who were at the risk of gestational dia-
betes revealed that G allele carriers of Cry1 rs2287161
polymorphisms presented less body weight loss and less
improvement in insulin secretion, HOMA-IR, and insu-
lin sensitivity than counterparts who were non-carriers
of the G allele [51]. Indeed, previous research has shown
that presence of the G risk allele of Cry1 rs2287161
Fig. 2 Interaction between dietary PUFA and Cry 1 genotypes on RMR disorder. Percentage of Types of RMR disorder across GC&CC and CC
genotypes base on low and high dietary PUFA. A) Percentage of RMR/ kg disorder in low intake across GG and GC&CC genotypes were
respiratory 56.2 and 45.7%., Percentage of RMR/kg disorder in high intake across GG, GC&CC genotypes were respiratory 43.8 and 55.3%. B)
Percentage of RMR per BMI disorder in low intake across GG and GC&CC genotypes were respiratory 55.1 and 38.9%., Percentage of RMR per BMI
disorder in high intake across GG and GC&CC genotypes were respiratory 44.9and 61.1%. C) Percentage of RMR per BSA disorder in low intake
across GG and GC&CC genotypes were respiratory 60.2 and 45%., Percentage of RMR per BSA disorder in high intake across GG and GC&CC
genotypes were respiratory 39.8and 55%. *P for interaction is for model adjusted (Potential confounders: education level, BMI, marriage status,
age, history of weight loss in past year, energy intake, economic status, RQ, and physical activity)
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polymorphisms was linked to decreased insulin secretion
and sensitivity [52]. In a study consisting of African-
American pregnant women, it was indicated that partici-
pants who were C allele carriers of Cry1 rs2287161 poly-
morphisms have lower fat intake than non-carriers [53].
Recently, Moradi et al. [54] posited that dietary fat in-
take may have an effect on RMR and RMR/FFM among
obese women. Indeed, Moradi et al. reported that the
AA genotype of PPARGC1A (rs11290186) had a positive
association with PUFAs intake, even after adjustment for
energy intake. Moreover, there was an interaction be-
tween total fat and SFAs intake with the PPARGC1A ge-
notypes, and, in line with the present study, the authors
found that women with a fat intake of more than 30% of
calories/day had lower RMR, as well as RMR/FFM [54].
The principal mechanism of the impact of gene vari-
ants on lipid metabolism, weight changes, and RMR
level is unknown. However, animal studies have demon-
strated the effect of fat on expression of clock gene
mRNA, lipogenic genes, and circadian balance [55, 56].
High fat intake is known to induce a decrease of the
mRNA, which is needed for several different enzymes,
including glutathione synthetase, superoxide dismutase,
and glutathione peroxidase [57]. A high-fat diet can elicit
the hyperacetylation of proteins, which is related to im-
paired mitochondrial function [58]. Moreover, after a
high-fat diet, hyperinsulinemia and insulin resistance
can occur through glucagon-like peptide-1 signaling,
which is related to reducing metabolic thermogenesis
and energy expenditure reduction [59].
In the present study, we did not find any significant
interaction between different types of RMRs across
PUFA categories. It has previously been shown that the
higher intake of PUFA is beneficial for glycemic indices
and lipid profile among individuals who carried G allele
of ADRB2 rs1042713 polymorphism [60]. Moreover, a
meta-analysis on feeding trials revealed that PUFA had
some effect in improving insulin resistance [61]. Also,
PUFA can, reportedly, alleviate the inflammation of adi-
pose tissue and oxidative stress [62]. Indeed, the extant
literature indicates that the composition of dietary fat is
important in insulin-related processes and probably
RMR. Therefore, more studies among different genders
and age groups are needed to better elucidate the im-
portance, and the manipulation, of dietary fat
composition.
To the best of our knowledge, this is the first investi-
gation on the association between GC genotypes of Cry1
rs2287161 polymorphisms, dietary fat, and the level of
RMR in women with overweight of obesity. However,
notwithstanding the novelty of the present study, several
limitations should be considered in the interpretation of
the results, including the small number of participants,
considering just one gender, and the cross-sectional
nature of the study. Indeed, it is, therefore, advocated
that cohort studies, that include both genders, be con-
ducted; in addition to appropriately powered sample
sizes.
Conclusion
In summary, the present study revealed that the high-fat
intake, with the CC +GC genotypes, may contribute to a
lower RMR in women with overweight of obesity. The
present study highlights the important role of gene-diet
interaction and the potential for personalized diet ther-
apy based on genetic characteristics. Moreover, this
study indicates important future research directions re-
garding the importance of genetic variants and their as-
sociation with circadian rhythms and changes in energy
expenditure. Further studies are needed to confirm the
veracity our findings and to clarify the precise mecha-
nism(s) of action.
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